Prasugrel (brand name Effient) is commonly called a blood thinner, but it’s more precisely an antiplatelet medication. It works by stopping blood platelets from clumping together, which reduces the risk of dangerous clots forming inside arteries. The distinction matters because “blood thinner” is a catch-all term that covers two different types of drugs that work in very different ways.
How Prasugrel Works
Your blood forms clots through two main pathways. One involves platelets, the tiny cell fragments that rush to a wound and stick together to plug it. The other involves clotting factors, proteins dissolved in your blood that create a mesh-like net to reinforce the plug. Prasugrel targets the first pathway. It permanently blocks a receptor on the surface of platelets that normally tells them to activate and clump. Once prasugrel binds to a platelet, that platelet can never respond to that activation signal again for the rest of its roughly 10-day lifespan.
This permanent, irreversible binding is a key feature. It means prasugrel’s effects don’t wear off quickly after you stop taking it. Your body has to produce entirely new platelets before normal clotting function returns.
Antiplatelet vs. Anticoagulant
Both antiplatelets and anticoagulants reduce clotting, and both get called “blood thinners” in everyday conversation. But they do different jobs. Antiplatelets like prasugrel keep platelets from sticking together. Anticoagulants (like warfarin or the newer direct oral anticoagulants) interfere with the clotting factor proteins, making it harder for the blood to form that reinforcing mesh. The American Stroke Association describes both categories as medicines that “reduce blood clotting in an artery, vein, or the heart,” but they’re prescribed for different conditions and carry different risk profiles.
Prasugrel falls squarely in the antiplatelet category. If your doctor or pharmacist calls it a blood thinner, they’re not wrong, but knowing it’s specifically an antiplatelet helps you understand why it was chosen for your situation and how it differs from other medications you might hear about.
What Prasugrel Is Prescribed For
Prasugrel is FDA-approved to reduce the risk of clot-related cardiovascular events in people with acute coronary syndrome (a sudden reduction in blood flow to the heart, including certain types of heart attack) who are undergoing a procedure called percutaneous coronary intervention, or PCI. During PCI, a cardiologist threads a catheter into a blocked artery and typically places a stent, a small metal scaffold that holds the artery open.
Stents are lifesaving, but they create a surface inside the artery where clots can form. That’s why prasugrel is almost always prescribed alongside low-dose aspirin, another antiplatelet. This combination, called dual antiplatelet therapy, is the standard approach after stent placement. The 2025 guidelines from the American College of Cardiology and American Heart Association recommend prasugrel or a similar drug called ticagrelor over the older option, clopidogrel, for patients with acute coronary syndrome undergoing PCI. The default duration for this dual therapy is at least 12 months unless you’re at high risk for bleeding.
Prasugrel vs. Clopidogrel
Clopidogrel is the most widely used drug in the same class, and many people wonder how prasugrel compares. In the large TRITON-TIMI 38 trial, patients taking prasugrel had a non-fatal heart attack rate of 7.1%, compared to 9.2% for those on clopidogrel. That’s a meaningful reduction. Rates of cardiovascular death were identical at 1.8% in both groups, so the advantage of prasugrel is primarily in preventing repeat heart attacks and stent clots rather than reducing death directly.
The tradeoff is bleeding. A network meta-analysis published in Circulation, pooling data from over 52,000 patients across 12 trials, found that prasugrel increased the risk of major bleeding by about 26% compared to clopidogrel. Prasugrel has also been shown to increase life-threatening bleeds specifically. This is why clopidogrel remains the preferred alternative for patients who have a higher baseline bleeding risk or who can’t safely take prasugrel.
Who Should Not Take Prasugrel
Prasugrel carries a boxed warning, the FDA’s most serious safety alert, for certain patient groups. It is contraindicated in anyone with a history of stroke or transient ischemic attack (sometimes called a mini-stroke). In the TRITON-TIMI 38 trial, subgroup analysis showed that these patients experienced net harm from prasugrel compared to clopidogrel: the extra bleeding risk outweighed any benefit in preventing clot events. It is also contraindicated in anyone with active bleeding, such as a peptic ulcer or bleeding inside the brain.
Older adults (75 and over) and people weighing less than 132 pounds (60 kg) may need a lower dose because their bleeding risk is elevated. These aren’t absolute contraindications, but guidelines recommend dose reduction be considered for both groups.
What Taking Prasugrel Means Day to Day
Because prasugrel makes your blood less able to form clots, you’ll bruise more easily and bleed longer from cuts. This is the drug doing exactly what it’s supposed to do, but it requires some practical awareness. Dental work, minor surgery, and even a hard bump can cause more bleeding than you’re used to. Any procedure that might involve cutting or puncturing skin typically requires coordination between your cardiologist and the other provider to decide whether to temporarily pause the medication.
Since prasugrel irreversibly disables platelets, stopping the drug doesn’t immediately restore normal clotting. It takes roughly 7 to 10 days for your body to replace enough platelets to clot normally, which is why planned surgeries often require stopping prasugrel about a week in advance. You should never stop taking it on your own, though. Stopping antiplatelet therapy prematurely after a stent is one of the strongest risk factors for stent thrombosis, a sudden clot inside the stent that can cause a heart attack.
The typical course is at least 12 months of dual therapy with aspirin. In some cases, treatment may be extended beyond a year if the risk of future clots is high and you’ve tolerated the medication well without significant bleeding. After the dual therapy period ends, your cardiologist will decide whether to continue one antiplatelet agent alone or transition to a different regimen based on your individual risk profile.